USA Bank Secrecy Act (BSA) Compliance Mandates Webinar: Latest Regulatory Developments for Financial Institutions (ON-DEMAND)
09 juil. 2024 04h35 HE
|
Research and Markets
Dublin, July 09, 2024 (GLOBE NEWSWIRE) -- The "BSA Important Issues: new mandates, requirements, and recommendations" report has been added to ResearchAndMarkets.com's offering. The landscape of...
FFIEC Bank Secrecy Act/Anti-Money Laundering Examination Manual Webinar: What Compliance Officers Really Need to Know? (ON-DEMAND)
09 juil. 2024 04h29 HE
|
Research and Markets
Dublin, July 09, 2024 (GLOBE NEWSWIRE) -- The "FFIEC BSA/AML Examination Manual: What Compliance Officers Really Need to Know?" training has been added to ResearchAndMarkets.com's offering.This...
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
01 juil. 2024 08h05 HE
|
Senti Biosciences, Inc.
The California Institute for Regenerative Medicines (CIRM) has awarded an $8 million grant to Senti Bio to support clinical development of SENTI-202.
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
17 juin 2024 09h45 HE
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83...
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
17 juin 2024 09h00 HE
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
Quantexa Debuts Q Assist, New Context Aware Generative AI Technology Suite
10 juin 2024 02h18 HE
|
Quantexa
New AI advancements are helping industry leaders get data ready for AI and make impact
Kura Oncology to Participate in Jefferies Global Healthcare Conference
29 mai 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Aptose Reports Results for the First Quarter 2024
14 mai 2024 16h01 HE
|
Aptose Biosciences, Inc.
Aptose Reports Results for the First Quarter 2024
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
14 mai 2024 07h30 HE
|
Kura Oncology, Inc.
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN...
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
13 mai 2024 08h15 HE
|
Senti Biosciences, Inc.
Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.